Skip to main content

In glucocorticoid-dependent polymyalgia rheumatica, tocilizumab improved a composite clinical outcome at 24 wk.

Publication ,  Journal Article
Pisetsky, DS
Published in: Ann Intern Med
January 2023

Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, et al. Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial. JAMA. 2022;328:1053-62. 36125471.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

January 2023

Volume

176

Issue

1

Start / End Page

JC5

Location

United States

Related Subject Headings

  • Polymyalgia Rheumatica
  • Humans
  • Glucocorticoids
  • Giant Cell Arteritis
  • General & Internal Medicine
  • Antibodies, Monoclonal, Humanized
  • 3202 Clinical sciences
  • 11 Medical and Health Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Pisetsky, D. S. (2023). In glucocorticoid-dependent polymyalgia rheumatica, tocilizumab improved a composite clinical outcome at 24 wk. Ann Intern Med, 176(1), JC5. https://doi.org/10.7326/J22-0107
Pisetsky, David S. “In glucocorticoid-dependent polymyalgia rheumatica, tocilizumab improved a composite clinical outcome at 24 wk.Ann Intern Med 176, no. 1 (January 2023): JC5. https://doi.org/10.7326/J22-0107.
Pisetsky, David S. “In glucocorticoid-dependent polymyalgia rheumatica, tocilizumab improved a composite clinical outcome at 24 wk.Ann Intern Med, vol. 176, no. 1, Jan. 2023, p. JC5. Pubmed, doi:10.7326/J22-0107.

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

January 2023

Volume

176

Issue

1

Start / End Page

JC5

Location

United States

Related Subject Headings

  • Polymyalgia Rheumatica
  • Humans
  • Glucocorticoids
  • Giant Cell Arteritis
  • General & Internal Medicine
  • Antibodies, Monoclonal, Humanized
  • 3202 Clinical sciences
  • 11 Medical and Health Sciences